Two Sigma Advisers’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-128,100
Closed -$2.08M 42
2025
Q4
$2.08M Buy
+128,100
New +$2.09M ﹤0.01% 1172
2025
Q3
Sell
-11,400
Closed -$133K 2318
2025
Q2
$133K Hold
11,400
﹤0.01% 2177
2025
Q1
$84.7K Sell
11,400
-40,200
-78% -$309K ﹤0.01% 2259
2024
Q4
$309K Buy
51,600
+41,200
+396% +$227K ﹤0.01% 1967
2024
Q3
$53.2K Buy
+10,400
New +$45.3K ﹤0.01% 2211
2024
Q2
Sell
-10,800
Closed -$34.7K 2417
2024
Q1
$34.7K Buy
10,800
+800
+8% +$3.1K ﹤0.01% 2370
2023
Q4
$49K Buy
+10,000
New +$45.6K ﹤0.01% 2398
2023
Q3
Sell
-14,800
Closed -$99.3K 2370
2023
Q2
$99.3K Sell
14,800
-1,100
-7% -$8.18K ﹤0.01% 2215
2023
Q1
$140K Sell
15,900
-19,800
-55% -$175K ﹤0.01% 2327
2022
Q4
$273K Sell
35,700
-15,400
-30% -$120K ﹤0.01% 2098
2022
Q3
$364K Buy
51,100
+4,700
+10% +$44.3K ﹤0.01% 1973
2022
Q2
$375K Buy
46,400
+34,300
+283% +$302K ﹤0.01% 2047
2022
Q1
$168K Buy
+12,100
New +$190K ﹤0.01% 2418
2021
Q2
Sell
-35,600
Closed -$1.43M 2426
2021
Q1
$1.43M Buy
+35,600
New +$1.93M ﹤0.01% 1443

Other funds holding ADPT

Two Sigma Advisers's ADPT Position: Q1 2026 in Review

Two Sigma Advisers sold out of Adaptive Biotechnologies (ADPT) in Q1 2026, closing a stake of 128,100 shares — an estimated $2.08M sold.

Two Sigma Advisers first reported a position in ADPT in Q1 2021 and held it in 14 quarters. The position peaked at $2.08M in Q4 2025. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Two Sigma Advisers reported no remaining Adaptive Biotechnologies position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 128,100 Adaptive Biotechnologies shares in Q1 2026, an estimated $2.08M.
  • Two Sigma Advisers first reported a position in Adaptive Biotechnologies in Q1 2021 and held it in 14 quarters.
  • Two Sigma Advisers's Adaptive Biotechnologies position peaked at $2.08M in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.